Dysgerminoma of the ovary: good prognosis even in advanced stages.
Dysgerminoma is a rare germ cell tumor of the ovary. It constitutes about 0.5% of all ovarian malignancies. During a 12-year period (1978-1989), 22 patients were treated at the National Cancer Institute, Cairo, Egypt. According to the FIGO classification system, 4 patients were allocated to Stage I, 2 were Stage II, 13 were Stage III, and 3 were Stage IV. The 5-year actuarial survival rate for all patients was 76%. Conservative treatment in addition to retrieval therapy upon recurrence could achieve 100% survival rate in Stage I patients. Surgery followed by irradiation resulted in a 66% 5-year actuarial survival rate in Stage III and 67% in Stage IV. Retroperitoneal lymph nodes seemed to have a better survival than peritoneal tumor extension. The adoption of an elective irradiation policy to the mediastinum and supraclavicular area seemed to have a good influence on prognosis. However, the extent of surgery performed could not be shown to affect survival.
Zaghloul
M S
MS
Radiotherapy Department, Cairo University, Egypt.
Khattab
T Y
TY
D000293:Adolescent; D000328:Adult; D002648:Child; D003131:Combined Modality Therapy; D004407:Dysgerminoma / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D015996:Survival Rate